市場調査レポート
商品コード
1226563
ビルタミマブ新薬の考察と市場予測(2032年)Birtamimab Emerging Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ビルタミマブ新薬の考察と市場予測(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
当レポートでは、ビルタミマブ新薬の主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)について調査分析し、作用機序、用法と用量、研究開発活動についての考察や、市場予測などを提供しています。
"Birtamimab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Birtamimab for AL Amyloidosis in the 7MM. A detailed picture of the Birtamimab for AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Birtamimab for AL Amyloidosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Birtamimab market forecast, analysis for AL Amyloidosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in AL Amyloidosis.
Birtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.
In preclinical studies, birtamimab has been shown to broadly react with a "cryptic" epitope exposed to misfolded kappa and lambda light chains that misfold and form amyloid. The proposed mechanism of action of birtamimab is to clear amyloid from organs and neutralize soluble aggregates that circulate in the bloodstream.
Birtamimab has been tested in nearly 300 patients with AL amyloidosis at the intended clinical dose of 24 mg/kg and was shown to be generally safe and well-tolerated in the clinical studies conducted to date. Birtamimab was previously evaluated in Phase III VITAL Study, a global multi-center, randomized, double-blind, placebo-controlled clinical study of newly diagnosed, treatment naive patients with AL amyloidosis and cardiac involvement. Results from the analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study revealed a significant survival benefit favoring birtamimab in these patients, with 74% of birtamimab-treated patients alive at 9 months versus 49% of patients in the control group.
Birtamimab is the only investigational therapeutic that has shown a significant survival benefit in Mayo Stage IV patients with AL amyloidosis in a placebo-controlled study.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Birtamimab Analytical Perspective by DelveInsight
This report provides a detailed market assessment of Birtamimab in AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of Birtamimab for AL Amyloidosis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions